MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference
MetaVia (NASDAQ: MTVA) announced it will hold an Advisory Committee meeting at the 9th Annual MASH-TAG 2025 Conference to discuss previously announced positive top-line 16-week results from their Phase 2a clinical trial. The trial evaluated DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH).
The conference is being held from January 9-11 at the Chateaux Deer Valley in Park City, Utah. MetaVia's management and clinical team will be available in the Exhibit Hall to discuss the trial results, and the presentation will be accessible on the company's website.
MetaVia (NASDAQ: MTVA) ha annunciato che terrà una riunione del Comitato Consultivo durante la 9ª Conferenza Annuale MASH-TAG 2025 per discutere dei risultati positivi a 16 settimane, già comunicati, del loro studio clinico di Fase 2a. Lo studio ha valutato DA-1241, un nuovo agonista del recettore accoppiato alla proteina G 119 (GPR119), in pazienti con presunta steatoepatite associata a disfunzione metabolica (MASH).
La conferenza si svolgerà dal 9 all'11 gennaio presso il Chateaux Deer Valley a Park City, Utah. Il management e il team clinico di MetaVia saranno disponibili nella Sala Espositiva per discutere i risultati dello studio, e la presentazione sarà accessibile sul sito web dell'azienda.
MetaVia (NASDAQ: MTVA) anunció que celebrará una reunión del Comité Asesor en la 9ª Conferencia Anual MASH-TAG 2025 para discutir los resultados positivos de 16 semanas previamente anunciados de su ensayo clínico de Fase 2a. El ensayo evaluó DA-1241, un nuevo agonista del receptor acoplado a proteína G 119 (GPR119), en pacientes con sospecha de esteatohepatitis asociada a disfunción metabólica (MASH).
La conferencia se llevará a cabo del 9 al 11 de enero en el Chateaux Deer Valley en Park City, Utah. La dirección y el equipo clínico de MetaVia estarán disponibles en el Salón de Exposiciones para discutir los resultados del ensayo, y la presentación estará accesible en el sitio web de la empresa.
MetaVia (NASDAQ: MTVA)는 9회 연례 MASH-TAG 2025 회의에서 16주 동안의 긍정적인 최상위 결과에 대해 논의하기 위해 자문 위원회 회의를 개최한다고 발표했습니다. 이 임상 시험은 대사 기능 장애와 관련된 지방간염(MASH)이 의심되는 환자를 대상으로 한 새로운 G-단백질 결합 수용체 119(GPR119) 작용제인 DA-1241를 평가했습니다.
회의는 유타주 파크시티의 Chateaux Deer Valley에서 1월 9일부터 11일까지 열립니다. MetaVia의 경영진 및 임상 팀은 전시 홀에서 시험 결과에 대해 논의할 수 있으며, 발표 내용은 회사 웹사이트에서 접근할 수 있습니다.
MetaVia (NASDAQ: MTVA) a annoncé qu'elle tiendra une réunion du Comité Consultatif lors de la 9ème Conférence Annuelle MASH-TAG 2025 pour discuter des résultats positifs de 16 semaines précédemment annoncés de leur essai clinique de Phase 2a. L'essai a évalué DA-1241, un nouvel agoniste du récepteur couplé à la protéine G 119 (GPR119), chez des patients présumés souffrir d'une stéatohépatite associée à une dysfonction métabolique (MASH).
La conférence se déroulera du 9 au 11 janvier au Chateaux Deer Valley à Park City, Utah. La direction et l'équipe clinique de MetaVia seront disponibles dans le Hall d'Exposition pour discuter des résultats de l'essai, et la présentation sera accessible sur le site web de l'entreprise.
MetaVia (NASDAQ: MTVA) gab bekannt, dass es während der 9. jährlichen MASH-TAG 2025-Konferenz ein Treffen des Beratungsausschusses abhalten wird, um die zuvor bekannt gegebenen positiven Ergebnisse der 16-wöchigen Phase-2a-Studie zu besprechen. Die Studie bewertete DA-1241, einen neuartigen Agonisten des G-Protein-gekoppelten Rezeptors 119 (GPR119), bei Patienten mit vermuteter metabolischer Dysfunktion-assoziierter Steatohepatitis (MASH).
Die Konferenz findet vom 9. bis 11. Januar im Chateaux Deer Valley in Park City, Utah, statt. Das Management und das klinische Team von MetaVia werden im Ausstellungsraum verfügbar sein, um die Studienergebnisse zu diskutieren, und die Präsentation wird auf der Unternehmenswebsite zugänglich sein.
- None.
- None.
A copy of the presentation will be available on the Events and Presentations section of the MetaVia website.
About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control.
For more information, please visit www.metaviatx.com.
Contacts:
MetaVia
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/metavia-to-hold-advisory-committee-meeting-at-the-9th-annual-mash-tag-2025-conference-302347510.html
SOURCE MetaVia Inc.
FAQ
What are the Phase 2a trial results for MetaVia's DA-1241 (MTVA) being discussed at MASH-TAG 2025?
When and where is MetaVia (MTVA) presenting at the MASH-TAG 2025 Conference?
How can investors access MetaVia's (MTVA) MASH-TAG 2025 presentation materials?
What is the therapeutic target of MetaVia's (MTVA) DA-1241 drug candidate?
